<DOC>
	<DOCNO>NCT02028819</DOCNO>
	<brief_summary>Ibalizumab humanize immunoglobulin G monoclonal antibody direct human T-cell receptor ( CD4 ) thus suppress HIV replication block entry HIV CD4+ lymphocytes . Ibalizumab complete phase I II clinical study HIV-negative HIV-infected individual show safety efficacy suppress HIV replication .</brief_summary>
	<brief_title>Compassionate Use Ibalizumab Treatment HIV Infection</brief_title>
	<detailed_description>1 . Ibalizumab humanize immunoglobulin G monoclonal antibody direct human T-cell receptor ( CD4 ) thus suppress HIV replication block entry HIV CD4+ lymphocytes . Ibalizumab pipeline FDA approval treat HIV infection . Phase I II clinical study complete HIV-negative HIV-infected individual show safety efficacy suppress HIV replication . 2 . Use medication require single patient IND obtain FDA patient require ibalizumab . An individual use IND approve FDA one patient treatment protocol ; The IND number 114515 . The manufacturer ibalizumab ( TaiMed Biologics , Inc ) ship drug directly Denver Health pharmacy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Adult patient diagnosis HIVinfection resistance intolerance currently available antiretroviral medication available United States additional drug need add regimen inadequate response exist therapy Patients HIV infection expect sensitive dolutegravir ibalizumab Patients qualify otherwise ineligible clinical trial medication currently approve treatment HIV infection U.S . Patients allergic severe adverse reaction dolutegravir ibalizumab past . Age &lt; 18 year &gt; 89 year Women may pregnant Prisoners decisionally challenge patient exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>